Understanding gut changes during Campylobacter infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates how gastrointestinal infections caused by Campylobacter affect the gut microbiota and mucosal lining. Researchers aim to identify changes during acute infection that may indicate a risk for developing chronic bowel issues, such as Irritable Bowel Syndrome (IBS). The study focuses on individuals who have tested positive for Campylobacter enteritis and examines various factors that may contribute to post-infectious IBS. By analyzing gut bacteria and mucosal changes, the study seeks to enhance understanding of the relationship between acute infections and long-term gastrointestinal health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* No abdominal surgery (except appendectomy and cholecystectomy)
* Stool culture or Polymerase chain reaction (PCR) positive enteritis with Campylobacter

Exclusion Criteria:

* History of IBS, Irritable Bowel Disease (IBD) (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease.
* History of gastroenteritis in six months prior to Campylobacter enteritis
* Pregnancy

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Madhusudan Grover, MBBS — Mayo Clinic
• Study coordinator: Margaret K Breen-Lyles, BS
• Email: Breen-Lyles.Margaret@mayo.edu
• Phone: 507-255-3520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity

  This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.

  Recruiting at 2 sites University of Palermo · Palermo, Palermo and 1 other locations · NCT07750535

• Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome

  This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07581756

• Brenipatide (LY3537031) for IBS with constipation

  This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.

  Recruiting at 64 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 69 other locations · NCT07545772

• Brenipatide (LY3537031) treatment for adults with IBS‑D

  This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.

  Recruiting at 80 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 88 other locations · NCT07545759

• Camlipixant for IBS-D and IBS-M: a test in adults

  This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.

  Recruiting at 114 sites Phase 2 GlaxoSmithKline · Anniston, Alabama and 113 other locations · NCT07519395

• Defining Objective Markers of Dietary Compliance in IBS

  This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT07494968

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.